NasdaqGS - Nasdaq Real Time Price USD

Inhibrx Biosciences, Inc. (INBX)

12.26

+0.28

+(2.34%)

At close: April 25 at 4:00:02 PM EDT

12.10

-0.16

(-1.31%)

Pre-Market: 5:12:33 AM EDT

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively.

PR Newswire 26 days ago

INBX
+2.34%
Inhibrx Biosciences Full Year 2024 Earnings: Beats Expectations

Inhibrx Biosciences ( NASDAQ:INBX ) Full Year 2024 Results Key Financial Results Net income: US$1.69b (up from...

Simply Wall St. last month

INBX
+2.34%
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because

PR Newswire last month

INBX
+2.34%
Inhibrx Prospective Colorectal Cancer Treatment Shows Encouraging Results, Trial Expansion Planned

Inhibrx Biosciences (INBX) late Tuesday released preliminary safety and efficacy data from phase 1 t

PREMIUM
MT Newswires 3 months ago

INBX
+2.34%
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). These results were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal A

PR Newswire 3 months ago

INBX
+2.34%
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security agreement (the "LSA") with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders provided a five-year term loan facility for up to $150 million (the "Credit Facility").

PR Newswire 3 months ago

INBX
+2.34%
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares

Key Insights Given the large stake in the stock by institutions, Inhibrx Biosciences' stock price might be vulnerable...

Simply Wall St. 5 months ago

INBX
+2.34%
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx Biosciences business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the sp

PR Newswire 5 months ago

INBX
+2.34%
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical stand

PR Newswire 5 months ago

INBX
+2.34%
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (NASDAQ:INBX) is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. This recent purchase by Director Kristiina Vuori aligns with the ongoing trend of insider confidence in the company's prospects.

GuruFocus.com 7 months ago

INBX
+2.34%
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights.

PR Newswire 8 months ago

INBX
+2.34%
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and

PR Newswire 10 months ago

INBX
+2.34%
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issu

PR Newswire 11 months ago

INBX
+2.34%
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off").

PR Newswire 11 months ago

INBX
+2.34%

Performance Overview

Return	INBX	S&P 500 (^GSPC)
YTD	-20.39%	-6.06%
1-Year	-33.55%	+9.44%
3-Year	-33.55%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Inhibrx Biosciences Full Year 2024 Earnings: Beats Expectations

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Prospective Colorectal Cancer Treatment Shows Encouraging Results, Trial Expansion Planned

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Performance Overview